Harnessing the Natural Killer Cytotoxic Response in Head and Neck Cancer
Description: A patient's own immune system is critically important for preventing and fighting cancer. A properly functioning immune system recognizes a tumor as foreign and serves to eliminate the cancer. Unfortunately, this fighting mechanism is often turned off by the tumor itself through a variety of processes including upregulation of a protein called programmed death-ligand 1 (PD-L1). When PD-L1 binds another protein called PD-1, which is often expressed on cancer fighting immune cells, these immune cells are turned off and the cancer is no longer recognized and removed by the immune system. Based on our understanding of this “checkpoint” controlling tumor growth, a promising strategy for improving cancer treatment is to block this inhibitory pathway, thereby recovering the capacity for the patient's own immune system to eliminate the cancer. In fact, nivolumab, a PD-1 antibody that blocks this negative interaction between PD-L1 and PD-1, has been shown to dramatically improve cancer outcomes in some patients. However, for unclear reasons, the majority do not achieve such an impressive response. Any new research that explains the basis for this frustrating spectrum of complete cure in some patients to no response in the majority, would have an enormous impact on cancer treatment outcomes.
Although it is known that nivolumab can activate the adaptive immune cell response resulting in tumor reduction in some patients, components of the innate immune system, specifically natural killer (NK) cells, may also be vitally important for robust immunogenic tumor cell killing. For this study, we propose to use a diabetic medication with minimal side effects called metformin, which we have shown activates a person’s own NK cells likely through a specific cancer signaling pathway. Importantly, as NK cells also express PD-1, we hypothesize that blocking both the PD-1/PD-L1 checkpoint with nivolumab, and negative signaling pathways with metformin in NK cells, will result in activation of both the adaptive and innate immune response leading to a more robust cytotoxic response. Here we propose to combine both treatments in patients in a clinical trial and to utilize patient’s tumor tissue and blood from the trial to determine why some patients respond and even more importantly, why some patients do not respond. We will use novel model systems such as organoids, three dimensional cell collections that are derived from individual patients, to allow us to directly test and predict patient responses in the laboratory. We will also analyze differential gene expression patterns in patients and relate to various responses to treatment. This will give vital insight to not only better understand and tailor specific treatment for each individual patient but also developing new more effective combinations for the future. We expect that the addition of metformin will increase the number of patients who respond to nivolumab and, in some cases, make the tumor disappear completely.
Funder: American Cancer Society
Amount: $792,000
Funding type: award
Start date: 2020-01-01
End date: 2023-12-31
Investigator: Trisha Wise-Draper (lead)
Institution: University of Cincinnati
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Funded outputs count: 4
Funder award ID: RSG-19-111-01-CCE
OpenAlex ID: G4698509195
